Financial News

My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

53.96 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Hims & Hers Health (HIMS): Buy, Sell, or Hold Post Q2 Earnings?
The past six months have been a windfall for Hims & Hers Health’s shareholders. The company’s stock price has jumped 55.7%, hitting $54 per share. This run-up might have investors contemplating their... 
Via StockStory
Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks
FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs without disclosing side effects, and called it "the most overt breach" of FDA... 
Via Benzinga
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the afternoon session after the stock extended its positive momentum as the company announced its expansion into the... 
Via StockStory
Topics Artificial Intelligence
Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts
Via Stocktwits
3 Cash-Producing Stocks on Our Watchlist
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions. 
Via StockStory
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the morning session after the stock's positive momentum continued as the company announced its expansion into the testosterone... 
Via StockStory
Hims & Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone
According to Stocktwits data, retail chatter around HIMS stock increased by 21% over the last 24 hours and by approximately 533% over the last 30 days as of the early hours on Wednesday. 
Via Stocktwits
Why Hims & Hers Health (HIMS) Stock Is Trading Up Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 3.8% in the afternoon session after the company announced its long-awaited entry into the testosterone replacement therapy market. 
Via StockStory
Hims & Hers Stock Jumps On Long-Awaited Foray Into Testosterone
The company is making a move into a highly anticipated area and partnering with a privately held pharmaceutical company. 
Via Investor's Business Daily
Topics ETFs
Hims & Hers Bets On Hormonal Health To Revive Investor Confidence
Hims & Hers is entering the hormonal health market with low testosterone treatments for men, aiming to expand its services as weight-loss drug sales slow and investor interest grows. 
Via Benzinga
Hims & Hers To Launch Low Testosterone Treatments for Men As Weight-Loss Drug Sales Slow
The telehealth company is expanding into hormonal health with plans to eventually add therapies for women in perimenopause and menopause. 
Via Stocktwits
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Why Hims & Hers Health (HIMS) Stock Is Up Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.9% in the morning session after it continued a rally from the previous day fueled by strong revenue guidance and supportive analyst... 
Via StockStory
Topics ETFs Economy
4 Top Stocks to Buy in September
Here are four stocks to buy now that could offer investors upside in both the short and long term. 
Via The Motley Fool
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire
Hims & Hers, which boasts a $9.7 billion market cap, is up 170% over the past year, though it's pulled back nearly 25% this past month. 
Via Benzinga
Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers
Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses. 
Via Benzinga
Topics ETFs
Healthcare Technology Stocks Q2 Highlights: Hims & Hers Health (NYSE:HIMS)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at healthcare technology stocks, starting... 
Via StockStory
Defiance Rolls Out Leveraged ETFs Targeting AMD, Supermicro, Palantir, Hims & Robinhood
Defiance ETFs introduces 5 new leveraged ETFs providing magnified exposure to popular tech, healthcare, and retail stocks, with a mix of growth and income. 
Via Benzinga
Topics ETFs
Got $5,000? 3 Tech Stocks to Buy and Hold for the Long Term
As the value of your investment portfolio rises over time, you will also be better equipped for retirement. 
Via The Motley Fool
Topics Artificial Intelligence
Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets
The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme. 
Via MarketBeat
Why Hims & Hers Health (HIMS) Stock Is Falling Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.4% in the afternoon session after investors took some profits off the table as markets awaited signals on future monetary policy from... 
Via StockStory
Topics ETFs Economy Lawsuit
What's Going On With Hims & Hers Shares Today?
Hims & Hers Health shares are trading lower Tuesday after GoodRx announces a collaboration with Novo Nordisk. 
Via Benzinga
Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4
A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors. 
Via MarketBeat
Topics Artificial Intelligence
Autonomous Vehicles Hit an Inflection Point; GPT-5 Is Here
Motley Fool Money checks in on some stock market news. 
Via The Motley Fool
Topics Economy
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets
GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S. 
Via Benzinga
CoreWeave, Applied Materials And Hims & Hers Are Among Top 10 Large Cap Losers Last Week (August 11-August 15): Are The Others In Your Portfolio?
Ten large-cap stocks, including CRWV, COHR & AMZN, were the worst performers last week. Weak results, downgrades, and FTC probe may be the reasons. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback